By Sherri Oslick --
About
Court Report: Each week we will report briefly on recently filed
biotech and pharma cases, and a few interesting cases will be selected
for periodic monitoring.
Shire LLC v. Nostrum Pharmaceuticals, Inc. et al.
3:08-cv-03309; filed July 2, 2008 in the District Court of New Jersey
Infringement of U.S. Patent Nos. 5,326,570 ("Advanced Drug Delivery System and Method of Treating Psychiatric, Neurological and Other Disorders with Carbamazepine," issued July 5, 1994) and 5,912,013 (same title, issued June 15, 1999) following a paragraph IV certification as part of Nostrum's filing of an amended ANDA to manufacture a generic version of Shire's Carbatrol® (carbamazepine, used to treat epilepsy and trigeminal neuralgia). View the complaint here.
E8 Pharmaceuticals LLC et al. v. Affymetrix, Inc.
1:08-cv-11132; filed July 1, 2008 in the District Court of Massachusetts
Infringement of U.S. Patent No. 6,703,228 ("Methods and Products Related to Genotyping and DNA Analysis," issued March 9, 2004) based on Affymetrix's use, manufacture, and sale of GeneChip® products. View the complaint here.
Bavarian Nordic A/S v. Oxford Biomedica PLC et al.
3:08-cv-01156; filed June 30, 2008 in the Southern District of California
Infringement of U.S. Patent Nos. 6,761,893 ("Modified Vaccinia Ankara Virus Variant," issued July 13, 2004), 6,913,752 (same title, issued July 5, 2005), and 7,335,364 (same title, issued February 26, 2008) based on Oxford's manufacture, use, and importation of, and induction of others to use its TroVax® products. View the complaint here.
AstraZeneca UK Ltd. et al. v. Dr. Reddy's Laboratories, Ltd. et al.
3:08-cv-03237; filed June 27, 2008 in the District Court of New Jersey
Infringement of U.S. Patent Nos. 5,319,097 ("Pharmaceutical Agents," issued June 7, 1994), 5,482,963 ("Pharmaceutical Agents Useful As Leukotriene Antagonists," issued January 9, 1996), and 6,143,775 ("Process For Preparing Pharmaceutical Composition Containing A Heterocyclic Amide," issued November 7, 2000) following a paragraph IV certification as part of Dr. Reddy's filing of an ANDA to manufacture a generic version of AstraZeneca's Accolate® (zafirlukast, used to treat asthma). View the complaint here.
Novartis Corp. et al. v. Cobalt Laboratories, Inc. et al.
3:08-cv-03237; filed June 27, 2008 in the District Court of New Jersey
Infringement of U.S. Patent No. 6,162,802 ("Synergistic Combination Therapy Using Benazepril and Amlodipine for the Treatment of Cardiovascular Disorders and Compositions Therefor," issued December 19, 2000) following a paragraph IV certification as part of Cobalt's filing of an ANDA to manufacture a generic version of Novartis' Lotrel® (amlodipine besylate/benazepril hydrochloride, used to treat hypertension). View the complaint here.
Wyeth v. Biovail Corp. et al.
1:08-cv-00390; filed June 26, 2008 in the District Court of Delaware
Infringement of U.S. Patent Nos. 6,274,171 ("Extended release formulation of venlafaxine hydrochloride," issued August 14, 2001), 6,403,120 (same title, issued June 11, 2002), and 6,419,958 (same title, issued July 16, 2002) following a paragraph IV certification as part of Biovail's filing of an ANDA to manufacture a generic version of Wyeth's EFFEXOR XR® (venlafaxine hydrochloride, extended release, used to treat depression). View the complaint here.
Comments